CN104602672B - 用于治疗细菌感染的定制脂质体 - Google Patents

用于治疗细菌感染的定制脂质体 Download PDF

Info

Publication number
CN104602672B
CN104602672B CN201380031384.7A CN201380031384A CN104602672B CN 104602672 B CN104602672 B CN 104602672B CN 201380031384 A CN201380031384 A CN 201380031384A CN 104602672 B CN104602672 B CN 104602672B
Authority
CN
China
Prior art keywords
sphingomyelin
cholesterol
empty liposomes
phosphatidylcholine
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380031384.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104602672A (zh
Inventor
E.巴比楚克
A.德拉伊格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
Original Assignee
Universitaet Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern filed Critical Universitaet Bern
Priority to CN201811433069.8A priority Critical patent/CN109549925B/zh
Publication of CN104602672A publication Critical patent/CN104602672A/zh
Application granted granted Critical
Publication of CN104602672B publication Critical patent/CN104602672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CN201380031384.7A 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体 Active CN104602672B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811433069.8A CN109549925B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12171924 2012-06-14
EP12171924.9 2012-06-14
EP13153039.6 2013-01-29
EP13153039 2013-01-29
PCT/EP2013/062207 WO2013186286A1 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811433069.8A Division CN109549925B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体

Publications (2)

Publication Number Publication Date
CN104602672A CN104602672A (zh) 2015-05-06
CN104602672B true CN104602672B (zh) 2018-12-25

Family

ID=48703423

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380031384.7A Active CN104602672B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体
CN201811433069.8A Active CN109549925B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811433069.8A Active CN109549925B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体

Country Status (19)

Country Link
US (4) US10744089B2 (enExample)
EP (2) EP2861214B1 (enExample)
JP (2) JP6382801B2 (enExample)
CN (2) CN104602672B (enExample)
AU (2) AU2013276565B2 (enExample)
BR (1) BR112014031278B1 (enExample)
CA (1) CA2875470C (enExample)
CY (1) CY1123337T1 (enExample)
DK (1) DK2861214T3 (enExample)
ES (1) ES2821502T3 (enExample)
HR (1) HRP20201761T1 (enExample)
HU (1) HUE051761T2 (enExample)
LT (1) LT2861214T (enExample)
PL (1) PL2861214T3 (enExample)
RS (1) RS60951B1 (enExample)
RU (1) RU2672106C2 (enExample)
SI (1) SI2861214T1 (enExample)
SM (1) SMT202000584T1 (enExample)
WO (1) WO2013186286A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861214B1 (en) * 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections
US20170000875A1 (en) 2013-12-02 2017-01-05 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
EP3397245A4 (en) * 2015-12-28 2019-08-28 MB Biotech Ltd. LIPOSOME FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2017177073A1 (en) * 2016-04-07 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use
PT3471732T (pt) 2016-06-16 2020-08-24 Combioxin Sa Lipossomas para o tratamento de infeções virais
WO2018158375A1 (en) * 2017-03-02 2018-09-07 Combioxin Sa Liposomes for inhibiting biofilm formation
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
CA3096968A1 (en) * 2018-04-17 2019-10-24 Samareh Azeredo Da Silveira Lajaunias Treatment of pneumonia
CN111971068B (zh) * 2018-04-20 2025-09-02 康柏辛股份有限公司 败血症和败血性休克的治疗
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
EP4188398A1 (en) * 2020-07-31 2023-06-07 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
CN115054577B (zh) * 2022-05-17 2024-06-21 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 纳米解毒剂及其在中和mrsa穿孔毒素的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004672A1 (en) * 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
NL9000207A (enExample) * 1990-01-29 1991-08-16 Duphar Int Res
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
PT1443900E (pt) * 2001-11-13 2012-08-01 Celator Pharmaceuticals Inc Composições de veículo lipídico com estabilidade melhorada no sangue
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
AU2003265241A1 (en) * 2002-05-23 2003-12-12 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US20040170677A1 (en) * 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
CN1939340A (zh) * 2005-09-29 2007-04-04 中国人民解放军军事医学科学院毒物药物研究所 脂质体制剂
US20080131497A1 (en) * 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
WO2008058156A2 (en) * 2006-11-06 2008-05-15 Jina Pharmaceuticals Inc. Guggulphospholipid methods and compositions
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
CN101623262B (zh) * 2009-08-24 2011-02-02 海南美大制药有限公司 一种五水头孢唑啉钠前体脂质体制剂
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
SG187770A1 (en) * 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
CN102327220B (zh) 2011-07-14 2012-09-26 海南灵康制药有限公司 一种氯雷他定脂质体固体制剂
EP2861214B1 (en) * 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004672A1 (en) * 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides

Also Published As

Publication number Publication date
LT2861214T (lt) 2020-12-28
US10744089B2 (en) 2020-08-18
CN109549925B (zh) 2022-06-17
WO2013186286A1 (en) 2013-12-19
RU2018138012A (ru) 2019-03-21
EP2861214B1 (en) 2020-08-05
BR112014031278B1 (pt) 2020-12-01
EP3782606A1 (en) 2021-02-24
US20200345639A1 (en) 2020-11-05
HRP20201761T1 (hr) 2020-12-25
AU2019201776B2 (en) 2020-11-12
SI2861214T1 (sl) 2021-01-29
US20150157570A1 (en) 2015-06-11
DK2861214T3 (da) 2020-10-12
US20220087934A1 (en) 2022-03-24
JP2018184470A (ja) 2018-11-22
AU2013276565A1 (en) 2014-12-18
AU2013276565B2 (en) 2018-12-20
JP6382801B2 (ja) 2018-08-29
SMT202000584T1 (it) 2020-11-10
JP2015519383A (ja) 2015-07-09
PL2861214T3 (pl) 2021-02-08
US20230031648A1 (en) 2023-02-02
ES2821502T3 (es) 2021-04-26
HK1210018A1 (en) 2016-04-15
CA2875470C (en) 2021-01-12
CN109549925A (zh) 2019-04-02
EP2861214A1 (en) 2015-04-22
AU2019201776A1 (en) 2019-04-04
RU2672106C2 (ru) 2018-11-12
RS60951B1 (sr) 2020-11-30
HUE051761T2 (hu) 2021-03-29
CY1123337T1 (el) 2021-12-31
CN104602672A (zh) 2015-05-06
BR112014031278A2 (pt) 2017-06-27
JP6656321B2 (ja) 2020-03-04
CA2875470A1 (en) 2013-12-19
RU2014148284A (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
CN104602672B (zh) 用于治疗细菌感染的定制脂质体
Qin et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics
US20150273025A1 (en) Apyrase treatments
JP2023503333A (ja) カンナビノイドおよび活性薬剤を使用した抗細菌処置
US20240397944A1 (en) Methods for biofilm disruption
RU2780026C2 (ru) Специально разработанные липосомы для лечения бактериальных инфекций
HK40046902A (en) Tailored liposomes for the treatment of bacterial infections
HK1210018B (zh) 用於治疗细菌感染的定制脂质体
Solleti Formulation and efficacy of liposome-encapsulated azithromycin for pulmonary infection due to Pseudomonias aeruginosa
Radhakrishnan et al. Insights into peptide mediated antibiofilm treatment in chronic wound: A bench to bedside approach
Marshall Volume 1 of 6
Snowden Bacterial biofilm formation and immune evasion mechanisms
Dalhoff Trends in Clinical Microbiology Membrane Interactions of Antibacterial Agents
WO2012020790A1 (ja) 感染症治療薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210018

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant